Opthea Share Price and Company Fundamentals



Price
$1.26
Change
-0.030 (-2.326%)
52 week
1.075 - 2.1

Last traded: Last Friday at 5:10 AM

Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema DME, as well as a first in class VEGF C/D inhibitors for treatment with VEGF A inhibitors for the treatment of wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

Key Metrics

PE ratio

-

PB ratio

2.32

Dividend yield

Beta

-0.15

Market cap

-

Enterprise value

-

Company profile

Primary activitiesOpthea is a drug development company developing innovative, biologics-based therapies for the treatment of eye disease.
Industry / SectorBiotechnology / Healthcare
Websitehttps://www.opthea.com
Mailing address650 Chapel Street Suite 0403 Level 4 South Yarra VIC 3141 Australia
Phone / Fax61 3 9826 0399 / 61 3 9824 0083
Share registryCOMPUTERSHARE INVESTOR SERVICES PTY LIMITED

Dividends

Opthea does not pay dividends.

Company Executives

As of Jan 2022, following are the company executives and directors listed on Opthea.

NameTitleAgeTotal Pay
Dr. Megan Baldwin M.A.I.C.D., MAICD, Ph.D.MD, CEO & Exec. Director47531.45k
Ms. Karen Adams CPAVP of Fin. & Company Sec.50701.33k
Ms. Judith J. Robertson B.A., M.B.A.Chief Commercial Officer604.25k
Ms. Annie LeeFin. & Operations Mang.
Dr. Richard ChadwickHead of Intellectual Property55
Dr. Michael GeromettaHead of Chemistry, Manufacturing & Controls Devel.57
Dr. Ian LeitchDirector of Clinical Research58
Dr. James GodingIndependent Consultant

Profitability and management effectiveness

Profit margin

0.00%

Operating margin

-41,484.03%

Return on assets

-26.38%

Return on equity

-50.42%

Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Opthea is and its enterprise value is .

Companies similar to Opthea (OPT)

Opthea (ASX:OPT) Frequently Asked Questions

1. What is Opthea's Stock Symbol?

Opthea trades on ASX under the ticker symbol "OPT".

2. What is Opthea's stock price today?

One share of OPT stock can currently be purchased for approximately $1.26.

3. How can I contact Opthea?

Opthea's mailing address is 650 Chapel Street Suite 0403 Level 4 South Yarra VIC 3141 Australia. The company can be reached via phone at 61 3 9826 0399.

4. What is Opthea's official website?

The official website of Opthea is https://www.opthea.com.

5. Which share registry manages Opthea's stock?

Opthea's stock is managed by COMPUTERSHARE INVESTOR SERVICES PTY LIMITED.